Alimera Sciences

Acquired

Focused on diseases affecting the retina

Alpharetta, United States · Founded 2003

Employees
51–200
Founded
2003
Business Model
B2B
Last Round
Venture RoundFeb 2014
Rounds
2
Acquired by
ANI PharmaceuticalsJun 2024

About

Alimera Sciences was a global pharmaceutical company focused on diseases affecting the retina. Its flagship product, ILUVIEN, is a sustained-release intravitreal implant approved for diabetic macular edema and non-infectious uveitis. The company served patients and physicians across the US and international markets before being acquired by ANI Pharmaceuticals in September 2024.

Summary

Alimera Sciences is a Biotech company based in Alpharetta, United States, founded in 2003. Its most recent funding was a Venture Round round in Feb 2014. Investors include ANI Pharmaceuticals, Palo Alto Investors and Sofinnova Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionJun 2024

Sign up to see all 4 rounds

IPO through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Alimera Sciences on Indexed.vc
<a href="https://indexed.vc/companies/alimera-sciences"><img src="https://indexed.vc/api/badge/company/alimera-sciences" alt="Alimera Sciences on Indexed.vc" width="260" height="76" /></a>